Abstract: Objective To evaluate the influence and safety of denosumab on bone mineral density(BMD) of lumbar spine in
women with low bone mass. Methods The clinical literatures concerning denosumab for the treatment of osteopenia or
osteoporosis in women were searched from Medline, Embase, Cochrane Central Register of Controlled Trials, Wanfang
database, China National Knowledge Infrastructure database, Chinese Biomedical Database. Randomized controlled trials
(RCT) were selected by the inclusive and exclusive criteria. The jadad scale was used in the quality assessment of included
studies. Meta-analysis of valid data picked from included studies was performed by RevMan 5.0.24 software. Results 5 RCT
were included in this meta-analysis. The results of meta-analysis using the fixed effects model showed that, the increase level
of lumbar BMD after 12 month was 5.45% (95% CI, 5.05%~5.84%) higher in denosumab group than in placebo control group(P<
0.00001). The serious adverse event, serious infection event and pack pain occurred during the followed-up were analysed
using fixed effects model. The results showed no significant difference between two groups. Conclusions Compared with
placebo control group, denosumab can significant increase the BMD of lumbar spine, and the safety of two groups is similar.